Cosunter(SZ:300436) Ge Long Hui·2025-07-16 14:25Group 1 - The core viewpoint is that Guangshentang's stock price has surged by 110% in the last 10 trading days, and over 422% since hitting a low in July last year, driven by policy support for innovative drugs and significant progress in hepatitis B treatment [1][6]. - The stock price increased from a low of 14.16 yuan per share to a high of 77.09 yuan per share [1]. - The recent surge has attracted speculative and quantitative trading, with notable net purchases from various investors, including 150 million yuan from Fuling Square Road [3][4]. Group 2 - Guangshentang's innovative hepatitis B drug GST-HG1311 has been included in the list of breakthrough therapy designations, indicating its potential clinical advantages as a new mechanism treatment [6][7]. - GST-HG1311 is an oral small molecule HBsAg inhibitor that significantly suppresses the expression of hepatitis B HBsAg, with no similar products currently available globally [6]. - Despite the potential of its hepatitis B drugs, Guangshentang continues to face ongoing financial losses, with net profits of -34.89 million yuan in 2021, -127 million yuan in 2022, and projected losses of -349 million yuan in 2023 [9]. Group 3 - As of July 15, Guangshentang's latest price-to-book ratio is 30.85, significantly higher than the industry average of 2.92, indicating a substantial valuation gap [10]. - Following the stock price surge, Guangshentang's current valuation is considered expensive [11].